Investigational Drug Information for PHA-793887
✉ Email this page to a colleague
What is the development status for investigational drug PHA-793887?
PHA-793887 is an investigational drug.
There have been 32 clinical trials for PHA-793887.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 4th 2020.
The most common disease conditions in clinical trials are Neoplasms, Leukemia, and Prostatic Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.
There are four US patents protecting this investigational drug and sixty-six international patents.
Summary for PHA-793887
| US Patents | 4 |
| International Patents | 66 |
| US Patent Applications | 36 |
| WIPO Patent Applications | 22 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 3 (2020-02-04) |
| Vendors | 70 |
Recent Clinical Trials for PHA-793887
| Title | Sponsor | Phase |
|---|---|---|
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II | Pharvaris Netherlands B.V. | Phase 2 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | Pharvaris Netherlands B.V. | Phase 2 |
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum) | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Phase 4 |
Clinical Trial Summary for PHA-793887
Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887
US Patents for PHA-793887
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PHA-793887 | See Plans and Pricing | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | See Plans and Pricing |
| PHA-793887 | See Plans and Pricing | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | Takara Bio Europe AB (Gothenburg, SE) | See Plans and Pricing |
| PHA-793887 | See Plans and Pricing | Quaternary amine compounds and antibody-drug conjugates thereof | Genentech, Inc. (South San Francisco, CA) | See Plans and Pricing |
| PHA-793887 | See Plans and Pricing | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | Pfizer Italia S.r.l. (Rome, IT) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PHA-793887
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PHA-793887 | Australia | AU2017351638 | 2036-10-26 | See Plans and Pricing |
| PHA-793887 | Canada | CA3044691 | 2036-10-26 | See Plans and Pricing |
| PHA-793887 | China | CN110730819 | 2036-10-26 | See Plans and Pricing |
| PHA-793887 | European Patent Office | EP3532605 | 2036-10-26 | See Plans and Pricing |
| PHA-793887 | World Intellectual Property Organization (WIPO) | WO2018076060 | 2036-10-26 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
